An observational study in Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME), sponsored by Bayer. Active, not recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Macular Edema by Bayer — none open to participants now, 1 under way, none of them phase 3. Macular Edema · Bayer.
Among the 16 studies in Macular Edema by Bayer, this one is the only one that started in 2025, is one of 6 observational ones, and was the 16th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 16 studies in Macular Edema by Bayer is open now. The open studies under Macular Edema, anywhere →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 71 across 127 observational studies indexed under Macular Edema.
Median enrollment 357 across the 10 interventional studies, 831 across the 6 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
1 of the studies in Macular Edema by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06929143BayerA Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Macular Edema by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied. In observational studies, only observations are made without participants receiving any advice or any changes to healthcare.
The eye disorders, nAMD and DME, affect the macula, the central part of the retina at the back of the eye. This leads to blurry vision or blind spots, making everyday activities like reading or sewing difficult. While nAMD is linked to aging, DME is related to diabetes. Both conditions require similar treatment to help improve vision.
Aflibercept 8 milligrams (mg) is already approved in Japan for doctors to prescribe to people with nAMD or DME. It is a drug injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF), which causes abnormal growth and leakage of blood vessels at the back of the eye.
The participants in this study are already receiving treatment with aflibercept 8 mg as part of their regular care from their doctors.
There is limited data available on the use of aflibercept 8 mg in Japan. Data from routine medical practice will inform treatment in Japanese and other Asian populations.
The main purpose of this study is to learn more about the disease and patient characteristics of Japanese participants with nAMD and/or DME who receive aflibercept 8 mg during their routine healthcare, and how they use it.
To learn this, the study will use 2 methods:
Method 1: Researchers will study the health details of participants when they first started aflibercept 8 mg.
Method 2: Researchers will study the participants' data collected over 1 year to see how they used aflibercept 8 mg.
The data will come from a claims database called DeSC Healthcare Inc. The data will be collected from April 2023 to March 2025 for Method 1, and from April 2023 to March 2026 for Method 2.
Researchers will only look at the information from participants in Japan.
In this study, only available data from routine care are collected. No visits or tests are required as part of this study.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 71 across 127 observational studies indexed under Macular Edema.
Browse Macular Edema studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Samples will be taken from the DeSC healthcare insurance database. This database contains information of 12 million individuals and has in a previous study been found to be demographically distributed in a similar manner to the Japanese population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with any International Classification of Diseases, Tenth revision (ICD-10) codes for nAMD or possible nAMD within the same month of the cohort entry date (except for patients who meet the nAMD/DME cohort definition).
Drug: Aflibercept (Eylea, BAY86-5321)
Patients with any ICD-10 codes for DME or possible DME within the same month of the cohort entry date (except for patients who meet the nAMD/DME cohort definition).
Drug: Aflibercept (Eylea, BAY86-5321)
Patients who have ICD-10 codes for nAMD, possible nAMD, DME, and possible DME within the same month of the cohort entry date.
Drug: Aflibercept (Eylea, BAY86-5321)
Patients with no ICD-10 codes for nAMD, possible nAMD, DME, and possible DME within the same month of the cohort entry date.
Drug: Aflibercept (Eylea, BAY86-5321)
8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).
Description of baseline characteristics of patients with nAMD or DME who initiated aflibercept 8 mg under real-world conditions.
Time frame: At baseline.
Description of the longitudinal patterns of treatment interval of patients with nAMD or DME who initiated aflibercept 8 mg.
Time frame: Within 12 months.
Change of treatment interval of patients with nAMD or DME who are treated with other anti-VEGF therapy.
Time frame: Before and 12 months after initiation of aflibercept 8 mg.
Number of injections of aflibercept 8 mg in patients with nAMD or DME.
Time frame: Within 3 months, 6 months, and 12 months after the first prescription date of aflibercept 8 mg.
Predicting factors of the patterns of the treatment interval of aflibercept 8 mg in patients with nAMD or DME.
Time frame: Within 12 months.
Proportion of patients who continue the aflibercept 8 mg.
Time frame: Within 12 months.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.